Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication
Top Cited Papers
Open Access
- 4 July 2006
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 7 (4), 257-265
- https://doi.org/10.1038/sj.tpj.6500406
Abstract
Codeine is an analgesic drug acting on μ-opiate receptors predominantly via its metabolite morphine, which is formed almost exclusively by the genetically polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Whereas it is known that individuals lacking CYP2D6 activity (poor metabolizers, PM) suffer from poor analgesia from codeine, ultra-fast metabolizers (UM) due to the CYP2D6 gene duplication may experience exaggerated and even potentially dangerous opioidergic effects and no systematical study has been performed so far on this question. A single dose of 30 mg codeine was administered to 12 UM of CYP2D6 substrates carrying a CYP2D6 gene duplication, 11 extensive metabolizers (EM) and three PM. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism methods and a single-base primer extension method for characterization of the gene-duplication alleles. Pharmacokinetics was measured over 24 h after drug intake and codeine and its metabolites in plasma and urine were analyzed by liquid chromatography with tandem mass spectrometry. Significant differences between the EM and UM groups were detected in areas under the plasma concentration versus time curves (AUCs) of morphine with a median (range) AUC of 11 (5–17) μg h l−1 in EMs and 16 (10–24) μg h l−1 in UM (P=0.02). In urine collected over 12 h, the metabolic ratios of the codeine+codeine-6-glucuronide divided by the sum of morphine+its glucuronides metabolites were 11 (6–17) in EMs and 9 (6–16) in UM (P=0.05). Ten of the 11 CYP2D6 UMs felt sedation (91%) compared to six (50%) of the 12 EMs (P=0.03). CYP2D6 genotypes predicting ultrarapid metabolism resulted in about 50% higher plasma concentrations of morphine and its glucuronides compared with the EM. No severe adverse effects were seen in the UMs in our study most likely because we used for safety reasons a low dose of only 30 mg. It might be good if physicians would know about the CYP2D6 duplication genotype of their patients before administering codeine.Keywords
This publication has 31 references indexed in Scilit:
- CYP2D6 Genotyping by a Multiplex Primer Extension ReactionClinical Chemistry, 2005
- Allele-Specific Change of Concentration and Functional Gene Dose for the Prediction of Steady-State Serum Concentrations of Amitriptyline and Nortriptyline in CYP2C19 and CYP2D6 Extensive and Intermediate MetabolizersClinical Chemistry, 2004
- Molecular diversity at the CYP2D6 locus in the Mediterranean regionEuropean Journal of Human Genetics, 2004
- A Frameshift Mutation and Alternate Splicing in Human Brain Generate a Functional Form of the Pseudogene Cytochrome P4502D7 That Demethylates Codeine to MorphineOnline Journal of Public Health Informatics, 2004
- A genetic association study of the mu opioid receptor and severe opioid dependencePsychiatric Genetics, 2003
- Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish populationClinical Pharmacology & Therapeutics, 1999
- Urinary Excretion of Codeine, Ethylmorphine, and Their MetabolitesTherapeutic Drug Monitoring, 1997
- PCR-based genotyping for duplicated and deleted CYP2D6 genesPharmacogenetics, 1996
- Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypesLife Sciences, 1995
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Biochemical and Biophysical Research Communications, 1988